Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Top Biologic Industry Leaders to Convene at Biologics World Korea 2013

Published: Friday, December 07, 2012
Last Updated: Friday, December 07, 2012
Bookmark and Share
Bringing together biologics drug innovators and bioprocess professionals from all around the world to discuss strategies in biosimilar and biobetter development, as well as cutting-edge advances in bioprocessing and bioanalytics.

The global biologics market is valued at an estimated US$149 bn and is expected to reach $230 bn by 2015. Monoclonal antibodies (mAbs) representing 32% of the market share is expected to be the fastest growing segment at 12.4% CAGR. South Korea’s biologics industry is well positioned to tap into this growing market. While Celltrion, Samsung Biologics and LG Life Sciences are grabbing the international headlines, innovative firms in South Korea such as Genexine, PharmAbcine, Alteogen and Ildong are building up an impressive innovative biologic pipeline that can rival international players.

The biologics landscape in South Korea is evolving fast. Knowing the who's and understanding the how's of the industry are crucial to stay competitive. Biologics World Korea 2013 conference will convene all these biologic players from South Korea and around the globe, to discuss the trend and challenges in biologic drug development. The conference will be chaired by Dr Byeong Doo Song, the President of Scripps Korea Antibody Institute.

The conference Keynote speaker is Dr Stanley Hong, the President of R&D of Celltrion, who led the first mAb biosimilar approval in the world. He said that the company will be interested in developing Biobetters. The company just launched its product, RemsimaTM worldwide and has already signed several distribution agreements with several leading pharma companies.

Another featured speaker is Dr Paul Coleman, the CEO of Hanwha Biologics, who successfully led the company in making its first landmark deal to license its newly developed biosimilar compound to Merck. Dr Coleman said that a key criterion in making a biosimilar globally available through partnerships is having the highest standards of quality in all aspects of the research and development processes. This is the key to success for the interest of companies who can access global markets. Hanwha Biologics has already garnered the interest of top companies in the world for its portfolio of other biosimilar compounds and is seeking to expand through further research and development of future biosimilar candidates.

The 2013 conference programme features industry visionary presentations from the Celltrion, Hanwha Biologics, Green Cross, Genexine, SK Chemicals, CJ CheilJedang, Mogam Biotech Institute, UCB Korea, Neopharm, KAIST, KRIBB, KBSI, PhamAbcine, Creagene, Merck Serono (USA), Protein Science Corporation (USA), NovImmune (Switzerland), Actokine (USA), Quest Pharma Tech (Canada), Wuxi AppTech Biologics (China) and many more. The conference programme runs on April 16-18 2013 at Sheraton Incheon Hotel. Technology providers such as BD Bioscience, Waters Korea, Dong-Il Shimadzu, Agilent Technologies and many others will also be there to showcase the latest solutions.

Since the inaugural success of Biologics World Korea 2012, the year 2013 conference will be more comprehensive to include biologic players at various stages of development. In the near term future, the innovations and partnerships will continue to drive the activities in this industry. With networking opportunities, presentation of valuable case studies and interactive discussion, the Biologics community can look forward to a fruitful gathering at the Biologics World Korea 2013. This conference aims to capture a holistic view of the issues challenging the industry, from market landscape to regulatory strategy, from bioprocessing to bioanalytics, from antibody engineering to clinical development.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More Than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

IMAPAC to Bring Together Over 150 Leading Industry Players
IMAPAC’s 3rd Biologics Korea gathering from 22-24 April 2014 in Seoul, Korea.
Wednesday, February 19, 2014
Regional Health Authorities to Meet and Discuss Russia’s 2020 Vision
Government aims for 50% of sold drugs to be manufactured in Russia by 2020.
Thursday, September 05, 2013
SE Asia Government Leaders to Discuss Move Towards Self-Sufficiency in Plasma Fractionation
Self-sufficiency is important to reduce costs, prevent blood shortages and meet the transfusion requirements of patients.
Thursday, August 29, 2013
IMAPAC Brings Together Blood Plasma Community
Upcoming Bioplasma gathering organized by IMAPAC to help facilitate the growth and innovation of quality plasma products in Asia.
Wednesday, July 17, 2013
Industry Leaders to Meet in Taiwan for Clinical Outsourcing and Collaboration Opportunities
Focused clinical trials meeting platform in Taipei, bringing together industry stakeholders, regulators and academics.
Monday, October 15, 2012
Last Days of the Early Bird Pricings for Biologics World China 2012
Keep up to date with China’s changing biopharma landscape by registering for Biologics World China 2012.
Monday, September 24, 2012
The Movement of China's Burgeoning Biologics Market
Facilitate innovation and manufacturing of affordable and high quality biologic drugs and vaccines in China.
Friday, August 24, 2012
Scientific News
Breaking Through the Barriers to Lab Innovation
Here we examine the drivers behind the move for greater innovation, the challenges and current trends in laboratory informatics, and the tools that can be used to break these barriers.
Education and Expense: The Barriers to Mass Spectrometry in Clinical Laboratories?
Here we examine the perceived barriers to mass spec in clinical laboratories and explore the possible drivers behind the recent shift in uptake of the technology in clinical settings.
Fruit Fly Pheromone Flags Great Real Estate for Starting a Family
Finding could aid efforts to control mosquito-borne diseases like malaria by manipulating odorants
Gene Editing Could Enable Pig-To-Human Organ Transplant
The largest number of simultaneous gene edits ever accomplished in the genome could help bridge the gap between organ transplant scarcity and the countless patients who need them.
Antioxidants Cause Malignant Melanoma to Metastasize Faster
Fresh research at Sahlgrenska Academy has found that antioxidants can double the rate of melanoma metastasis in mice.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Adult High Blood Pressure Risk Identifiable in Childhood
Groups of people at risk of having high blood pressure and other related health issues by age 38 can be identified in childhood, new University of Otago research suggests.
Analyzing Protein Structures in Their Native Environment
Enhanced-sensitivity NMR could reveal new clues to how proteins fold.
Supercoiled DNA is Far More Dynamic Than the “Watson-Crick” Double Helix
Researchers have imaged in unprecedented detail the three-dimensional structure of supercoiled DNA, revealing that its shape is much more dynamic than the well-known double helix.
Mini-kidneys Successfully Grown from Stem Cells
Researchers from Murdoch Childrens Research Institute have perfected a method of turning stem cells into mini-kidneys for use in drug screening, disease modelling and cell therapy.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos